Amo Pharma Company
Rare and orphan diseases, phase 3 clinical trials of GSK 3beta inhibitor, also glutamate modulator (Rett syndrome).
Technology:
AgeTech Companies
Industry:
Healthcare
Headquarters:
United Kingdom
Founded Date:
Undisclosed
Employees Number:
1-10
Funding Status:
Private Equity
Estimated Revenue:
$10M to $50M
Register and Claim Ownership